MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Acumen Pharmaceuticals, Inc. (ABOS)

Acumen Pharmaceuticals, Inc. (ABOS)

|||

Balance Sheets Overview

Current Ratio
246.57%
Quick Ratio
246.57%
Cash Ratio
126.88%
Debt to Asset Ratio
50.64%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Restricted cash
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Debt, short-term
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
59,443
51,796
53,989
46,832
Marketable securities
50,754
76,602
62,876
79,777
Prepaid expenses and other current assets
5,316
4,696
5,387
5,544
Total current assets
115,513
133,094
122,252
132,153
Marketable securities, long-term
-
-
0
9,443
Restricted cash
231
231
231
232
Other assets, long-term
263
304
350
393
Total assets
116,007
133,629
122,833
142,221
Accounts payable
13,379
1,655
554
682
Accrued clinical trial expenses
6,263
8,183
10,616
9,884
Accrued expenses and other current liabilities
7,533
5,268
10,072
7,792
Debt, short-term
19,673
14,123
8,765
3,598
Total current liabilities
46,848
29,229
30,007
21,956
Debt, long-term
11,896
16,924
22,396
27,053
Other liabilities, long-term
-
-
0
39
Total liabilities
58,744
46,153
52,403
49,048
Common stock, 0.0001 par value 300,000,000 shares authorized as of june30, 2026 and december31, 2025 72,314,714 and 60,575,369 shares issued and outstanding as of june30, 2026 and december31, 2025, respectively
7
7
6
6
Additional paid-in capital
557,186
554,647
516,803
514,382
Accumulated deficit
-499,917
-467,199
-446,462
-421,324
Accumulated other comprehensive (loss) income
-13
21
83
109
Total stockholders equity
57,263
87,476
70,430
93,173
Total liabilities and stockholders equity
116,007
133,629
122,833
142,221
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$59,443K (61.49%↑ Y/Y)Marketable securities$50,754K (-52.37%↓ Y/Y)Prepaid expenses andother current assets$5,316K (5.58%↑ Y/Y)Total current assets$115,513K (-22.16%↓ Y/Y)Other assets,long-term$263K (-43.32%↓ Y/Y)Restricted cash$231K (-0.43%↓ Y/Y)Total assets$116,007K (-32.51%↓ Y/Y)Total liabilities andstockholders equity$116,007K (-32.51%↓ Y/Y)Total liabilities$58,744K (7.16%↑ Y/Y)Total stockholdersequity$57,263K (-51.09%↓ Y/Y)Accumulated deficit-$499,917K (-26.60%↓ Y/Y)Accumulated othercomprehensive (loss) income-$13K (-156.52%↓ Y/Y)Total currentliabilities$46,848K (88.44%↑ Y/Y)Debt, long-term$11,896K (-60.19%↓ Y/Y)Additional paid-in capital$557,186K (8.84%↑ Y/Y)Common stock, 0.0001par value...$7K (16.67%↑ Y/Y)Debt, short-term$19,673K Accounts payable$13,379K (536.19%↑ Y/Y)Accrued expenses andother current...$7,533K (-35.34%↓ Y/Y)Accrued clinical trialexpenses$6,263K (-43.62%↓ Y/Y)